Volume 26, Number 4—April 2020
Synopsis
Decreased Susceptibility to Azithromycin in Clinical Shigella Isolates Associated with HIV and Sexually Transmitted Bacterial Diseases, Minnesota, USA, 2012–2015
Table 1
Inhibition zone, mm | No. (%) isolates |
|||
---|---|---|---|---|
S. sonnei, n = 559 | S. flexneri, n = 125† | S. boydi, n = 5 | S. dysenteriae, n = 2 | |
6 | 24 (4) | 18 (14) | 1 (20) | 0 |
8 | 0 | 1 (0.8) | 0 | 0 |
12 | 0 | 1 (0.8) | 0 | 0 |
14 | 0 | 1 (0.8) | 0 | 0 |
15 | 1 (0.2) | 0 | 0 | 0 |
17 | 2 (0.4) | 0 | 0 | 0 |
18 | 3 (1) | 0 | 0 | 0 |
19 | 5 (1) | 2 (2) | 0 | 0 |
20 | 23 (4) | 4 (3) | 0 | 0 |
21–25 | 442 (79) | 48 (38) | 2 (40) | 1 (50) |
26–30 | 58 (10) | 44 (35) | 2 (40) | 0 |
>30 | 1 (0.2) | 6 (5) | 0 | 1 (50) |
*Decreased susceptibility to azithromycin is defined as no zone of inhibition (6 mm) by disk diffusion using a disk containing 15 µg of azithromycin.
†Decreased susceptibility to azithromycin is defined as a <15 mm zone of inhibition with a disk containing 15 µg of azithromycin.
Page created: March 17, 2020
Page updated: March 17, 2020
Page reviewed: March 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.